Order Article Reprints

Jamrozik M, Piska K, Bucki A, Koczurkiewicz-Adamczyk P, Sapa M, Władyka B, Pękala E, Kołaczkowski M. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Molecules. 2023; 28(9):3767. https://doi.org/10.3390/molecules28093767

Jamrozik, Marek, Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Michał Sapa, Benedykt Władyka, Elżbieta Pękala, and Marcin Kołaczkowski. 2023. "In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics" Molecules 28, no. 9: 3767. https://doi.org/10.3390/molecules28093767

Jamrozik, M., Piska, K., Bucki, A., Koczurkiewicz-Adamczyk, P., Sapa, M., Władyka, B., Pękala, E., & Kołaczkowski, M. (2023). In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Molecules, 28(9), 3767. https://doi.org/10.3390/molecules28093767